JP2019519227A5 - - Google Patents

Download PDF

Info

Publication number
JP2019519227A5
JP2019519227A5 JP2018561962A JP2018561962A JP2019519227A5 JP 2019519227 A5 JP2019519227 A5 JP 2019519227A5 JP 2018561962 A JP2018561962 A JP 2018561962A JP 2018561962 A JP2018561962 A JP 2018561962A JP 2019519227 A5 JP2019519227 A5 JP 2019519227A5
Authority
JP
Japan
Prior art keywords
fusion protein
protein complex
soluble fusion
soluble
acid sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018561962A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019519227A (ja
JP7037506B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/034656 external-priority patent/WO2017205726A1/en
Publication of JP2019519227A publication Critical patent/JP2019519227A/ja
Publication of JP2019519227A5 publication Critical patent/JP2019519227A5/ja
Application granted granted Critical
Publication of JP7037506B2 publication Critical patent/JP7037506B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018561962A 2016-05-27 2017-05-26 Cd3結合ドメインを有する多量体il-15系分子の構築及び特性評価 Active JP7037506B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342311P 2016-05-27 2016-05-27
US62/342,311 2016-05-27
US201662397236P 2016-09-20 2016-09-20
US62/397,236 2016-09-20
PCT/US2017/034656 WO2017205726A1 (en) 2016-05-27 2017-05-26 Construction and characterization of multimeric il-15-based molecules with cd3 binding domains

Publications (3)

Publication Number Publication Date
JP2019519227A JP2019519227A (ja) 2019-07-11
JP2019519227A5 true JP2019519227A5 (https=) 2020-06-18
JP7037506B2 JP7037506B2 (ja) 2022-03-16

Family

ID=60412970

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018561962A Active JP7037506B2 (ja) 2016-05-27 2017-05-26 Cd3結合ドメインを有する多量体il-15系分子の構築及び特性評価

Country Status (7)

Country Link
US (1) US10865230B2 (https=)
EP (1) EP3464352B1 (https=)
JP (1) JP7037506B2 (https=)
KR (2) KR102463844B1 (https=)
CN (2) CN109496217B (https=)
AU (1) AU2017271593B2 (https=)
WO (1) WO2017205726A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
SI3094351T1 (sl) * 2014-01-15 2022-05-31 Kadmon Corporation, Llc Imunomodulatorna sredstva
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス, インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN118562016A (zh) 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス, インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
AU2018385699B2 (en) * 2017-12-14 2024-08-15 Regeneron Pharmaceuticals, Inc. Daric interleukin receptors
TW201938196A (zh) * 2018-01-18 2019-10-01 美商南特生物科學股份有限公司 融合蛋白擴展
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗muc1抗体およびil−15を含む融合タンパク質構築物
TW202003011A (zh) 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗PDL1、IL-15及TGF-β受體組合分子
US11267866B2 (en) 2018-04-04 2022-03-08 Nant Holdings Ip, Llc Immunoglobulin complex comprising interleukin-15
WO2020037120A1 (en) 2018-08-16 2020-02-20 Nantbio, Inc. Il7-il15 txm compositions and methods
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2021041886A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified n-810 and methods therefor
US20230097573A1 (en) * 2019-10-16 2023-03-30 Lg Chem, Ltd. Neonatal fc receptor binding affimers
CN111690069B (zh) * 2019-11-13 2022-04-19 中国科学技术大学 一种IL-15/SuIL-15Rα-mFc-γ4复合体蛋白及其构造方法、应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN114106195B (zh) * 2020-08-27 2024-09-17 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
WO2022042576A1 (zh) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
US20230405122A1 (en) * 2020-11-24 2023-12-21 City Of Hope Compositions and uses of psca targeted chimeric antigen receptor modified cells
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
BR112023021886A8 (pt) * 2021-04-22 2024-01-09 Guangdong Fapon Biopharma Inc Polipeptídeo de fusão biespecífico multifuncional
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
JP7734994B2 (ja) * 2021-06-02 2025-09-08 クレ バイオテクノロジ (シャンハイ) カンパニー リミテッド 抗cd3抗体変異体、融合タンパク質および適用
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116143942A (zh) * 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN115806628A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1994004689A1 (en) 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ,ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
CA2697612A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP2016531100A (ja) * 2013-07-12 2016-10-06 ザイムワークス,インコーポレイテッド 二重特異的なcd3及びcd19抗原結合構築物
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
KR20180125435A (ko) 2015-09-25 2018-11-23 알토 바이오사이언스 코포레이션 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies

Similar Documents

Publication Publication Date Title
JP2019519227A5 (https=)
JP2020114828A5 (https=)
JP2017504578A5 (https=)
JP2019033754A5 (https=)
JP2020074776A5 (https=)
JP2016527314A5 (https=)
RU2015129640A (ru) Связанные дисульфидом мультивалентные многофункциональные белки, содержащие молекулы гкгс класса 1
RU2015144098A (ru) Четырехвалентные биспецифические антитела
JP2010527919A5 (https=)
JP2019516665A5 (https=)
JP2018528786A5 (https=)
JP5874118B2 (ja) IgA結合性ペプチド及びそれによるIgAの精製
JP2016000731A5 (https=)
JP2018537415A5 (https=)
JP2009524422A5 (https=)
JP2014528696A5 (https=)
JP2017504577A5 (https=)
JP2014158485A5 (https=)
EA201400046A1 (ru) Удаление клеток-мишеней с помощью циркулирующих вирусспецифических цитотоксических т-клеток с использованием содержащих гкгс класса i комплексов
HRP20130877T1 (hr) Antitijela koja neutraliziraju humani citomegalovirus i njihova primjena
RU2018104703A (ru) Опухолеспецифичное антитело против egfr и его применение
JP2019535315A5 (https=)
Zhu et al. COMBODY: one‐domain antibody multimer with improved avidity
RU2018141360A (ru) Contorsbody - одноцепочечный связывающий мишень агент
JP6985572B2 (ja) 単鎖抗体のスクリーニング方法及び単鎖抗体